Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marilyn R. Semenchuk"'
Publikováno v:
Neurology. 57:1583-1588
To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain.This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360b86e9bad8fca032e1a3123d0977ea
https://doi.org/10.1212/wnl.57.9.1583
https://doi.org/10.1212/wnl.57.9.1583
Autor:
Bennet Davis, Marilyn R. Semenchuk
Publikováno v:
The Clinical Journal of Pain. 16:6-11
The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain.Open-label treatment design.Outpatient pain clinic, University of Arizona Health Sciences Center, Tucson, Arizona.Twenty-two pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec29ccdad96033710efa546977aa209
https://doi.org/10.1097/00002508-200003000-00002
https://doi.org/10.1097/00002508-200003000-00002
Autor:
Marilyn R. Semenchuk, Scott J. Sherman
Publikováno v:
The Journal of Pain. 1:285-292
The purpose of this research trial is to assess the effectiveness and tolerability of tizanidine in neuropathic pain. In an open-label study, patients with neuropathic pain received 1 to 4 mg of tizanidine once daily for 7 days, followed by weekly do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64725234f8d08af12c7783b676e28126
https://doi.org/10.1054/jpai.2000.9435
https://doi.org/10.1054/jpai.2000.9435
Autor:
David M. Labiner, Marilyn R. Semenchuk
Publikováno v:
Journal of Psychiatric Practice. 3:334-342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::719dffa4af0b1ace51ad9faac829a943
https://doi.org/10.1097/00131746-199711000-00002
https://doi.org/10.1097/00131746-199711000-00002
Autor:
Marilyn R, Semenchuk
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 3(9)
Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::42afb0bf912f659e11f1a35c8e412a3b
https://pubmed.ncbi.nlm.nih.gov/12498014
https://pubmed.ncbi.nlm.nih.gov/12498014
Autor:
Semenchuk, Marilyn R., Sherman, Scott
Publikováno v:
In Journal of Pain January 2000 1(4):285-292
Publikováno v:
Epilepsia (Series 4); Dec2002, Vol. 43 Issue 12, p1447-1452, 6p